NO911949L - Tgf-beta-preparater. - Google Patents

Tgf-beta-preparater.

Info

Publication number
NO911949L
NO911949L NO91911949A NO911949A NO911949L NO 911949 L NO911949 L NO 911949L NO 91911949 A NO91911949 A NO 91911949A NO 911949 A NO911949 A NO 911949A NO 911949 L NO911949 L NO 911949L
Authority
NO
Norway
Prior art keywords
tgf
prepared
beta formulation
beta
formulation
Prior art date
Application number
NO91911949A
Other languages
English (en)
Other versions
NO911949D0 (no
Inventor
Michael James Newman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO911949D0 publication Critical patent/NO911949D0/no
Publication of NO911949L publication Critical patent/NO911949L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO91911949A 1990-05-22 1991-05-21 Tgf-beta-preparater. NO911949L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/527,215 US5147854A (en) 1990-05-22 1990-05-22 Tgf-b compositions and method

Publications (2)

Publication Number Publication Date
NO911949D0 NO911949D0 (no) 1991-05-21
NO911949L true NO911949L (no) 1991-11-25

Family

ID=24100576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91911949A NO911949L (no) 1990-05-22 1991-05-21 Tgf-beta-preparater.

Country Status (16)

Country Link
US (1) US5147854A (no)
EP (1) EP0462398A1 (no)
JP (1) JPH05213772A (no)
KR (1) KR910019638A (no)
AU (1) AU636489B2 (no)
CA (1) CA2042973A1 (no)
FI (1) FI912462L (no)
HU (1) HUT57599A (no)
IE (1) IE911736A1 (no)
IL (1) IL98177A0 (no)
MC (1) MC2259A1 (no)
NO (1) NO911949L (no)
NZ (1) NZ238179A (no)
PT (1) PT97728A (no)
YU (1) YU89891A (no)
ZA (1) ZA913647B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248666A (en) * 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
US4890152A (en) * 1986-02-14 1989-12-26 Matsushita Electric Works, Ltd. Plastic molded chip carrier package and method of fabricating the same
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
US5726058A (en) * 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
DK0671909T3 (da) * 1992-12-01 2001-03-19 Biotie Therapies Corp Syndecanstimulering af cellulær differentiering
DE4304394A1 (en) * 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
RU2246315C2 (ru) * 1993-08-10 2005-02-20 Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
RU2157406C2 (ru) * 1993-08-10 2000-10-10 Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА
US6017727A (en) * 1994-03-07 2000-01-25 Biotie Therapies Ltd. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
WO1998004680A1 (en) * 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
US5891925A (en) * 1997-06-27 1999-04-06 Abbott Laboratories Diagnostic method for assessing the serum cholesterol response to low diets
AU6232899A (en) * 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
US6767541B2 (en) * 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US20040229791A1 (en) * 2002-12-31 2004-11-18 Jung San Huang Compositions and methods of modulating TGF-beta activity by fatty acids
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
US20060186078A1 (en) * 2005-02-22 2006-08-24 David Ziegenhorn Screw on dispensing closure with structure for preventing removal
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments
CA2699454C (en) * 2007-08-27 2012-07-24 Auxagen, Inc. Methods for inhibiting tgf-.beta.
CN102118981A (zh) * 2008-06-10 2011-07-06 帝斯曼知识产权资产管理有限公司 植物提取物和pufa组合
WO2010033507A1 (en) * 2008-09-16 2010-03-25 St. Louis University Method of enhancing tgf-beta signalling
US10322125B2 (en) 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4326055A (en) * 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4816442A (en) * 1986-11-07 1989-03-28 Collagen Corporation Method of inhibiting tumor growth sensitive to CIF-βtreatment

Also Published As

Publication number Publication date
FI912462A0 (fi) 1991-05-21
IE911736A1 (en) 1991-12-04
KR910019638A (ko) 1991-12-19
EP0462398A1 (en) 1991-12-27
MC2259A1 (fr) 1993-04-26
ZA913647B (en) 1992-02-26
US5147854A (en) 1992-09-15
AU7713991A (en) 1991-12-12
FI912462A7 (fi) 1991-11-23
HUT57599A (en) 1991-12-30
NO911949D0 (no) 1991-05-21
FI912462L (fi) 1991-11-23
HU911672D0 (en) 1991-11-28
JPH05213772A (ja) 1993-08-24
CA2042973A1 (en) 1991-11-23
IL98177A0 (en) 1992-06-21
YU89891A (sh) 1994-06-10
NZ238179A (en) 1993-04-28
PT97728A (pt) 1992-02-28
AU636489B2 (en) 1993-04-29

Similar Documents

Publication Publication Date Title
NO911949D0 (no) Tgf-beta-preparater.
DK0394026T3 (da) Formulering
MX9203481A (es) Formulaciones.
DE69011988D1 (de) Lagerstabile Azadirachtin-Formulierung.
FI933122L (fi) Foerbaettrad herbicidisk formulering
BR9006655A (pt) Composicao polimerica
FI921142L (fi) Gelformulationer.
FI910310A0 (fi) Acesulfam-k-innehaollande komposition.
FI921491L (fi) Antimalariakompositioner.
FI904444A0 (fi) Aktiva limkompositioner.
FI915768L (fi) Komposition foer rengoering av maolningar.
FI904407L (fi) Faestorgan.
FI922270L (fi) Diltiazemiformulation
DE69021872D1 (de) Modifizierte Lösungsmittelzusammensetzungen.
FI914255L (fi) I uv-ljus haerdbar organopolysil- oxankomposition.
FI911308L (fi) Lipopeptidderivat.
NO912598D0 (no) Hypokalori-matsammensetning.
FI911749L (fi) Haorvaextreglerande komposition.
FI913796L (fi) Pappersoeverdragningskomposition.
FI903130A7 (fi) Haorvaordsshampoo innehaollande en laongkedjig alkoholkomponent.
ITRM910273A1 (it) Composizione insetticida.
FI911208L (fi) Haollare foer kombinerat kirurgiskt sutur-naol-instrument.
MX9204183A (es) Formulacion de prostagladina e1
FI911501L (fi) Liposomkomposition foer parenteralt bruk.
FI923371A0 (fi) En farmaceutisk formulation.